Table 3.

Comparison of CI-AKI and non-CI-AKI group in terms of different qualitative risk factors

Variable	N = 86 CI-AKI AKIN (−) n (%)	N = 9 CI-AKI AKIN (+) n (%)	p*
Men	58 (67.4%)	8 (88.9%)	0.184
Obesity	35 (40.7%)	4 (44.4%)	0.828
Cigarette smoking	52 (60.5%)	6 (66.7%)	0.716
hsTnT—positive	25 (29.1%)	3 (33.3%)	0.347
ACS (UA or NSTEMI)	47 (54.7%)	7 (77.8%)	0.183
History of acute kidney injury	4 (4.7%)	1 (11.1%)	0.398
History of myocardial infarction	35 (40.7%)	6 (66.7%)	0.135
Peripheral artery disease	12 (13.9%)	4 (44.4%)	0.020
Arterial hypertension	82 (95.3%)	9 (100.0%)	0.509
Atrial fibrillation	20 (23.3%)	1 (11.1%)	0.403
Dyslipidemia	79 (91.9%)	9 (100%)	0.374
DM/IFG/IGT	31 (36.0%)	6 (66.7%)	0.073
Mild proteinuria	8 (9.4%)	1 (11.1%)	0.869
Chronic obstructive pulmonary disease	8 (9.3%)	1 (11.1%)	0.860
Radial vascular access	17 (19.8%)	1 (11.1%)	0.528
Coronary artery anomaly	3 (3.5%)	2 (22.2%)	0.017
Left main disease	5 (5.8%)	5 (55.6%)	<0.0001
SYNTAX score >32 pts	4 (4.7%)	6 (66.7%)	<0.0001
Referral for CABG	9 (10.5%)	5 (55.6%)	0.0003
Iso-osmolar contrast media	8 (9.3%)	2 (22.2%)	0.229
Time of procedure: 6 am—noon	43 (50.0%)	1 (11.1%)	0.026
Time of procedure: noon—6 pm	30 (34.9%)	6 (66.7%)	0.062
PCI ad hoc	38 (44.2%)	4 (44.4%)	0.988
Hypotension during procedure	4 (4.6%)	1 (11.1%)	0.409
Mitral valve insufficiency (mild–moderate)	56 (65.1%)	5 (55.6%)	0.569
Regional wall motion abnormalities	45 (52.3%)	7 (77.8%)	0.144
LVEF < 50%	21 (24.4%)	3 (33.3%)	0.558
E/e′ ≥ 12	20 (23.3%)	2 (22.2%)	0.930
Statin therapy prior to contrast exposure	75 (87.2%)	9 (100.0%)	0.254
NSAIDs	8 (9.3%)	5 (55.6%)	0.001

ACS acute coronary syndrome, UA unstable angina, NSTEMI non-ST-elevation myocardial infarction, IFG impaired fasting glucose, IGT impaired glucose tolerance, PCI percutaneous coronary intervention, NSAID non-steroidal anti-inflammatory drug, ACEI/ARB angiotensin converting enzyme inhibitor/angiotensin receptor blocker, LVEF left ventricular ejection fraction

*Pearson’s Chi² test